{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:28:20Z","timestamp":1781285300646,"version":"3.54.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Therapeutic drug monitoring (TDM) for lithium is recommended in guidelines; however, the prevalence of TDM for lithium is seldom reported. We have therefore investigated the prevalence of TDM for lithium and evaluated the impact of the regulatory warnings requiring routine TDM for lithium.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Monthly claims data covering around 1.7 million persons aged 20\u201374 years old during the period January 1, 2005, and March 31, 2015, were evaluated. All patients who had at least one prescription for lithium were selected and included to calculate the annual prevalence of TDM for lithium. Also we assessed whether the 2 regulatory warnings requiring routine TDM for lithium and issued in April 2012 and September 2012 had an impact on TDM for lithium, using segmented regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Between 2005 and 2014, 136,956 prescriptions of lithium were issued to 5823 patients, and the annual prevalence of TDM for lithium was 14.9% (95% confidence interval, 14.7%\u201315.1%). The analysis revealed that the mean prevalence increased abruptly by 6.9% (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.001) after the regulatory warning in April 2012, whereas that the warning in September 2012 decreased by 1.2% (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.47). There was no significant change in trends of period prevalence after the warning in April 2012 (April 2012\u2013August 2012) compared with prevalence before the warning (April 2010\u2013March 2012). Similarly, no significant change was observed in the trends before (April 2012\u2013August 2012) and after (September 2012\u2013March 2014) the subsequent warning in September 2012.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Results showed that the prevalence of TDM for lithium was low, although TDM for lithium was strongly recommended by the guidelines. Regulatory warnings requiring compliance with the measurement of blood levels during treatment with lithium, issued twice during the five-month period, were associated with an increase in the prevalence of TDM for lithium. However, the impact of the second warning was not remarkable compared with the first warning.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000483","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T15:53:46Z","timestamp":1518105226000},"page":"252-256","source":"Crossref","is-referenced-by-count":20,"title":["Prevalence of Therapeutic Drug Monitoring for Lithium and the Impact of Regulatory Warnings: Analysis Using Japanese Claims Database"],"prefix":"10.1097","volume":"40","author":[{"given":"Nobuhiro","family":"Ooba","sequence":"first","affiliation":[{"name":"Nihon University School of Pharmacy, Funabashi, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Nihon University School of Pharmacy, Funabashi, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Nihon University School of Pharmacy, Funabashi, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Nihon University School of Pharmacy, Funabashi, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Nihon University School of Pharmacy, Funabashi, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Obara","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Public Health, Hygiene and Epidemiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Kubota","sequence":"additional","affiliation":[{"name":"NPO Drug Safety Research Unit Japan, Bunkyo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Nihon University School of Pharmacy, Funabashi, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/FTD.0b013e318296a2ff","article-title":"Therapeutic drug monitoring of psychotropic drugs in China: a nationwide survey","volume":"35","author":"Guo","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00023210-200923040-00005","article-title":"Lithium: updated human knowledge using an evidence-based approach. Part II: clinical pharmacology and therapeutic monitoring","volume":"23","author":"Grandjean","year":"2009","journal-title":"CNS Drugs."},{"key":"R4-20230928","first-page":"501","article-title":"Therapeutic tricyclic antidepressant drug monitoring in younger and older depressive patients","volume":"58","author":"Radziwo\u0144-Zaleska","year":"2006","journal-title":"Pharmacol Rep."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/pcn.12060","article-title":"Guideline for treatment of bipolar disorder by the Japanese society of mood disorders, 2012","volume":"67","author":"Kanba","year":"2013","journal-title":"Psychiatry Clin Neurosci."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1111\/j.1365-2125.2001.00174.x","article-title":"Therapeutic drug monitoring of psychotropic medications","volume":"52","author":"Mitchell","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"R7-20230928","first-page":"121","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 2: review, grading of the evidence, and a precise algorithm","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int J Neuropsychopharmacol."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0031-1286281","article-title":"Therapeutic drug monitoring in Italian psychiatry","volume":"44","author":"Conca","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00007691-199812000-00002","article-title":"Delivery of therapeutic drug monitoring services: survey of Australasian clinical pharmacology laboratories","volume":"20","author":"Morris","year":"1998","journal-title":"Ther Drug Monit."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/FTD.0000000000000167","article-title":"Prevalence of therapeutic drug monitoring for antidepressants and antipsychotics in stockholm, Sweden: a longitudinal analysis","volume":"37","author":"Wallerstedt","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2188\/jea.JE20090066","article-title":"Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage","volume":"20","author":"Kimura","year":"2010","journal-title":"J Epidemiol."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40345-016-0068-y","article-title":"Lithium side effects and toxicity: prevalence and management strategies","volume":"4","author":"Gitlin","year":"2016","journal-title":"Int J Bipolar Disord."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1176\/ajp.156.7.1014","article-title":"Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder","volume":"156","author":"Marcus","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/pds.725","article-title":"Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States","volume":"11","author":"Enger","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1001\/jama.284.23.3036","article-title":"Contraindicated use of cisapride: impact of food and drug administration regulatory action","volume":"284","author":"Smalley","year":"2000","journal-title":"JAMA"},{"key":"R21-20230928","first-page":"1500","article-title":"Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs","volume":"92","author":"Ratanajamit","year":"2009","journal-title":"J Med Assoc Thai."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/pds.830","article-title":"Impact of cisapride label changes on codispensing of contraindicated medications","volume":"12","author":"Guo","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1067\/mcp.2002.129503","article-title":"The impact of wording in \u201cDear doctor\u201d letters and in black box labels","volume":"72","author":"Weatherby","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00007691-198001000-00009","article-title":"Serum concentration and clinical supervision in monitoring of lithium treatment","volume":"2","author":"Amdisen","year":"1980","journal-title":"Ther Drug Monit."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/13651501.2014.981542","article-title":"Therapeutic drug monitoring: perspectives of psychiatrists in Turkey","volume":"19","author":"Eryilmaz","year":"2015","journal-title":"Int J Psychiatry Clin Pract."},{"key":"R26-20230928","first-page":"151","article-title":"Appropriateness of the use of serum lithium assays","volume":"22","author":"Karki","year":"1988","journal-title":"Drug Intell Clin Pharm."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/bmj.304.6826.552","article-title":"Lithium treatment: prescribing and monitoring habits in hospital and general practice","volume":"304","author":"Kehoe","year":"1992","journal-title":"BMJ"},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/01.jcp.0000246208.11153.b6","article-title":"Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders","volume":"26","author":"Mann","year":"2006","journal-title":"J Clin Psychopharmacol."},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-244X-10-80","article-title":"Standards of lithium monitoring in mental health trusts in the UK","volume":"10","author":"Collins","year":"2010","journal-title":"BMC Psychiatry"},{"key":"R30-20230928","first-page":"481","article-title":"Study on lithium monitoring amongst patients in a community mental health and primary care setting in rural England","volume":"29","author":"Savage","year":"2017","journal-title":"Psychiatr Danub."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bdi.12128","article-title":"Monitoring lithium therapy: the impact of a quality improvement programme in the UK","volume":"15","author":"Paton","year":"2013","journal-title":"Bipolar Disord."},{"key":"R32-20230928","first-page":"1954","article-title":"Appropriateness of therapeutic drug monitoring for lithium","volume":"89","author":"Ratanajamit","year":"2006","journal-title":"J Med Assoc Thai"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T02:20:47Z","timestamp":1719800447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000483","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}